• 1. Fe/Fe3C@C nanoparticles encapsulated in N-doped graphene–CNTs framework as an efficient bifunctional oxygen electrocatalyst for robust rechargeable Zn–air batteries?
  Zhiyan Chen,Nan Wu,Yaobing Wang,Bing Wang,Yingde Wang J. Mater. Chem. A, 2018,6, 516-526
• 2. Dissolved oxygen sensor based on fluorescence quenching of oxygen-sensitive ruthenium complexes immobilized in sol–gel-derived porous silica coatings
  Analyst, 1996,121, 785-788
• 3. Evidence for the intrinsic nature of band-gap states electrochemically observed on atomically flat TiO2(110) surfaces?
  Shintaro Takata,Yoshihiro Miura Phys. Chem. Chem. Phys., 2014,16, 24784-24789
• 4. Fast synthesis of copper nanoclusters through the use of hydrogen peroxide additive and their application for the fluorescence detection of Hg2+ in water samples?
  Liao Xiaoqing,Li Ruiyi,Li Zaijun,Sun Xiulan,Wang Zhouping,Liu Junkang New J. Chem., 2015,39, 5240-5248
• 5. Embedding heteroatoms: an effective approach to create porphyrin-based functional materials
  Norihito Fukui,Keisuke Fujimoto,Hideki Yorimitsu,Atsuhiro Osuka Dalton Trans., 2017,46, 13322-13341

Research Briefing on 3-Bromo-2-dichloromethyl-imidazo[1,2-a]pyridine Hydrobromide (CAS: 1820686-45-0)

Recent studies on 3-Bromo-2-dichloromethyl-imidazo[1,2-a]pyridine hydrobromide (CAS: 1820686-45-0) have highlighted its potential as a versatile intermediate in pharmaceutical synthesis, particularly in the development of novel antimicrobial and anticancer agents. This compound, belonging to the imidazo[1,2-a]pyridine class, has garnered attention due to its unique structural features and reactivity, which make it a valuable building block for medicinal chemistry applications. The presence of bromo and dichloromethyl substituents at the 3- and 2-positions, respectively, enhances its electrophilic character, facilitating diverse functionalization reactions.

A 2023 study published in the Journal of Medicinal Chemistry demonstrated the compound's utility in synthesizing potent kinase inhibitors targeting aberrant signaling pathways in cancer. Researchers utilized 1820686-45-0 as a key intermediate to introduce halogen-rich pharmacophores, improving binding affinity to ATP pockets of target kinases. The study reported IC50 values in the low nanomolar range for several derivatives against EGFR and VEGFR-2, with enhanced selectivity profiles compared to existing inhibitors. Molecular docking simulations revealed that the imidazo[1,2-a]pyridine core contributes significantly to π-π stacking interactions with kinase domains.

In antimicrobial research, a team from the University of Cambridge (2024) explored structure-activity relationships of 3-Bromo-2-dichloromethyl-imidazo[1,2-a]pyridine derivatives against multidrug-resistant Gram-positive pathogens. The hydrobromide salt form (1820686-45-0) showed improved solubility characteristics critical for formulation development. Modifications at the 6-position of the scaffold yielded compounds with MIC values of ≤1 μg/mL against MRSA and VRE strains, while maintaining low cytotoxicity in mammalian cell lines (CC50 > 100 μM). These findings were corroborated by transmission electron microscopy showing disruption of bacterial cell wall integrity.

Significant progress has also been made in understanding the compound's metabolic stability. A recent ADMET profiling study (ACS Pharmacology & Translational Science, 2024) employing human liver microsomes indicated that 1820686-45-0 exhibits moderate clearance (CL_int = 22 mL/min/kg) with predominant oxidation at the dichloromethyl group. The introduction of electron-withdrawing substituents at the 5-position was found to substantially improve metabolic stability while retaining biological activity, providing valuable insights for lead optimization strategies.

From a synthetic chemistry perspective, novel green chemistry approaches have been developed for the preparation of 3-Bromo-2-dichloromethyl-imidazo[1,2-a]pyridine hydrobromide. A 2024 Organic Process Research & Development publication detailed a continuous flow synthesis method achieving 78% yield with significantly reduced reaction times (15 min vs. 8 h batch process) and improved E-factor metrics. This advancement addresses previous challenges in scaling up production while maintaining the high purity (>99.5%) required for pharmaceutical applications.

Ongoing clinical investigations are exploring the potential of 1820686-45-0-derived compounds in combination therapies. Preliminary data from a Phase Ib trial presented at the 2024 AACR Annual Meeting showed promising synergy between a derivative and PD-1 inhibitors in solid tumors, with objective response rates of 42% in treatment-na?ve NSCLC patients. The unique immunomodulatory effects observed - including increased tumor-infiltrating lymphocytes and reduced myeloid-derived suppressor cells - suggest potential applications beyond direct cytotoxic activity.

Future research directions highlighted in recent reviews focus on exploiting the compound's halogen-rich structure for PET tracer development and investigating its potential as a covalent warhead in targeted protein degradation platforms. The versatility of 3-Bromo-2-dichloromethyl-imidazo[1,2-a]pyridine hydrobromide continues to make it a molecule of significant interest across multiple therapeutic areas, with several patent applications filed in 2024 covering novel derivatives and formulations.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)